CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel)
- Written by PR Newswire
![]() |
SHANGHAI, Aug. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the completion of enrollment in the pivotal Phase II clinical trial of satricabtagene autoleucel ("satri-cel",...















